Skip to main content
About Us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Our Approach
PDE4 Prodrug
Publications
Pipeline
Overview
PALI-2108
Investors & News
Overview
Press Releases
Events & Presentations
Analyst Coverage
SEC Filings
Corporate Governance
IR Resources
Stock Information
FAQs
Email Alerts
Contact
PALI-2108, a Next-Generation Oral PDE4 Inhibitor Prodrug, Demonstrates Localized Ileocolonic Exposure with Favorable Tolerability in IBD
brandedpixel
September 4th, 2026
No Comments
Comments are closed